Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Use of PET for monitoring cancer therapy and for predicting outcome.
342
Zitationen
1
Autoren
2005
Jahr
Abstract
PET with the glucose analog (18)F-FDG is increasingly used to monitor tumor response in patients undergoing chemotherapy and chemoradiotherapy. Numerous studies have shown that (18)F-FDG PET is an accurate test for differentiating residual viable tumor tissue from therapy-induced fibrosis. Furthermore, quantitative assessment of therapy-induced changes in tumor (18)F-FDG uptake may allow the prediction of tumor response and patient outcome very early in the course of therapy. Treatment may be adjusted according to the chemosensitivity and radiosensitivity of the tumor tissue in an individual patient. Thus, (18)F-FDG PET has an enormous potential to reduce the side effects and costs of ineffective therapy. This review focuses on the practical aspects of (18)F-FDG PET for treatment monitoring and on how to perform a quantitative assessment of tumor (18)F-FDG uptake in clinical studies.
Ähnliche Arbeiten
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 · 29.148 Zit.
Robust uncertainty principles: exact signal reconstruction from highly incomplete frequency information
2006 · 15.725 Zit.
Image processing with ImageJ
2004 · 11.903 Zit.
Fast robust automated brain extraction
2002 · 10.776 Zit.
Improved Optimization for the Robust and Accurate Linear Registration and Motion Correction of Brain Images
2002 · 10.610 Zit.